We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
- Authors
Cortés-Sempere, M; de Miguel, M P; Pernía, O; Rodriguez, C; de Castro Carpeño, J; Nistal, M; Conde, E; López-Ríos, F; Belda-Iniesta, C; Perona, R; de Caceres, I Ibanez
- Abstract
Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines and 25 NSCLC patients with known IGFBP-3 methylation status and response to CDDP. Then, to provide a helpful tool that enables clinicians to identify patients with a potential response to CDDP, we have calculated the association between our diagnostic test and the true outcome of analyzed samples in terms of cisplatin IC50; the inhibitory concentration that kills 50% of the cell population. Our results suggest that loss of IGFBP-3 expression by promoter methylation in tumor cells treated with CDDP may activate the PI3K/AKT pathway through the specific derepression of IGFIR signaling, inducing resistance to CDDP. This study also provides a predictive test for clinical practice with an accuracy and precision of 0.84 and 0.9, respectively, (P=0.0062). We present a biomarker test that could provide clinicians with a robust tool with which to decide on the use of CDDP, improving patient clinical outcomes.
- Subjects
LUNG cancer; INSULIN-like growth factor-binding proteins; PROMOTERS (Genetics); METHYLATION; CISPLATIN; INSULIN-like growth factor receptors; PROTEIN kinase B; CANCER cells
- Publication
Oncogene, 2013, Vol 32, Issue 10, p1274
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/onc.2012.146